Drug Type Oncolytic virus |
Synonyms VSV-IFNβ-NIS |
Target |
Mechanism IFNβ stimulants(Interferon beta stimulants), NIS stimulants(solute carrier family 5 member 5 stimulants), Cell death stimulants + [1] |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization Vyriad, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colorectal Cancer | Phase 2 | BR | Vyriad, Inc.Startup | 24 Apr 2020 |
Colorectal Cancer | Phase 2 | US | Vyriad, Inc.Startup | 24 Apr 2020 |
Melanoma | Phase 2 | BR | Vyriad, Inc.Startup | 24 Apr 2020 |
Melanoma | Phase 2 | US | Vyriad, Inc.Startup | 24 Apr 2020 |
Squamous Cell Carcinoma of Head and Neck | Phase 2 | US | Vyriad, Inc.Startup | 24 Apr 2020 |
Squamous Cell Carcinoma of Head and Neck | Phase 2 | BR | Vyriad, Inc.Startup | 24 Apr 2020 |
Neuroendocrine Carcinoma | Phase 2 | US | Vyriad, Inc.Startup | 09 Apr 2019 |
Non-Small Cell Lung Cancer | Phase 2 | US | Vyriad, Inc.Startup | 09 Apr 2019 |
Malignant Solid Neoplasm | Preclinical | US | Vyriad, Inc.Startup | 17 Apr 2017 |
NCT03017820 (ASCO2023) Manual | Phase 1 | 43 | (dghivwtnwe) = Grades 3 and higher AEs were hematologic with transient lymphopenia (63.6%), neutropenia (36.4%) being the most common. mwxitlhbir (isrelnpkgx ) View more | Positive | 31 May 2023 | ||
Phase 1 | 30 | (odaeziivuj) = cxsowleael aymsrfkqop (nakbxqazrb ) | Positive | 31 May 2023 | |||
NCT03017820 (ASCO2021) Manual | Phase 1 | 15 | (ibtjrcdmgg) = CRS grades 1 (6.7%) and 2 (46.6%) were the non-hematologic AEs of note. hjxdmykrzc (wcxildadhj ) View more | Positive | 20 May 2021 |